(415) 476-3831 (appts)
(415) 476-0616 (fax)

Box 0106, UCSF; San Francisco, CA 94143-0106

additional websites:

UCSF Physician Referral Directory
Matthay Faculty Profile

Bryn Mawr College, Bryn Mawr, PA, B.A., 1969, Chemistry
University of Pennsylvania, Philadelphia, PA, M.D., 1973, Medicine
University of Colorado, Denver, CO, Resident, 1976, Pediatrics
University of California, San Francisco, CA, Fellow, 1979, Pediatric Hematology/Oncology

(From 130)

Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP,. Seeger RC, Weinberg VK, Price D. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16:229-236.

Goldberg SS, DeSantes K, Huberty JP, Price D,. Hasegawa BH, Reynolds CP, Seeger RC, Hattner R, Matthay KK. Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma. Med Pediatr Oncol, 1998; 30:339-346.

Matthay KK, Villablanca JG, Seeger RC, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing R, Stram DO, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341:1165-1173.

Haas-Kogan D, Swift PS, Selch M, Haase G, Seeger RC, Gerbing R, Stram DO, Matthay KK. The role of radiotherapy for high-risk neuroblastoma: A ChildrenÕs Cancer Group study. Int J Radiat Oncol Biol Phys 2003; 56: 28-39.

Matthay KK, Brisse H, Couanet D, Couturier J, Benard J, Mosseri V, Edeline V, Lumbroso J, Valteau-Couanet D, Michon J. Central nervous system metastases in neuroblastoma: Radiological, clinical and biological features in 23 patients. Cancer 2003; 98(1)155-165.

Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM, Valteau-Couanet D, Hartmann O, Michon J. Early metastatic response by 123I-metaiodobenzylguanidine scintigraphy: correlation with overall response and event-free survival in stage 4 neuroblastoma. J. Clin Oncol. 2003; 21:2486-2491.

Weiss B, Vora A, Huberty J, Hawkins R, Matthay KK. Secondary myelodysplastic syndrome and leukemia following 131I- metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Ped Hematol Oncol 2003; 25:543-547.

Dubois S, Messina J, Maris J, Huberty J, Glidden D, Veatch J, Charron M, Hawkins R, Matthay K. Hematologic toxicity of high dose 131I-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol, 2004; 22:2452-60.

Howard J, Maris JM, Kersun LS, Huberty JP, Hawkins RA, Matthay KK. Tumor Response and Toxicity with Multiple infusions of High Dose 131I-MIBG for Refractory Neuroblastoma. Pediatr Blood and Cancer 2004; Oct 15 (ePub). 2005 Mar;44(3):232-9.

Schmidt ML, Lal A, Seeger RC, Maris J, Shimada H, OÕLeary M, Gerbing R, Matthay KK. Favorable prognosis for patients ages 12-18 months with stage 4 MYCN-non-amplified neuroblastoma: A ChildrenÕs Cancer Group study. J Clin Oncol 2005; Aug 22, ePub; 23:6474-6480.

London WB, Castleberry RP, Matthay KK, Look AT, Seeger B, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL. Evidence for an Age Cut-off Greater than 365 days for Neuroblastoma Risk Group Stratification in the ChildrenÕs Oncology Group (COG). J Clin Oncol 2005; 23:6459-6465.

Attiyeh EF, London WB, Mosse YP, Yang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look T, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM. Chromosome 1p and 11q deletions independently predict for neuroblastoma outcome: A ChildrenÕs Oncology Group Study. N Engl J Med 2005; 353:2243-53.

Matthay KK, Tan J, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Phase I Dose Escalation of 131I-Metaiodobenzylguanidine with Myeloablative Chemotherapy and Autologous Stem Cell Transplant in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006; 24:500-06.

Messina JA, Cheng S-C, Franc BL, Charron M, Shulkin B, To B, Maris JM, Yanik G, Hawkins RA, Matthay KK. Evaluation of semi-quantitative scoring system for Metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood & Cancer 2006; ePub ahead of print.

Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Eickhoff J, Reisfeld RA, Gillies SD,Sondel PM. A Phase I Clinical Trial of the Hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: A Study of the ChildrenÕs Oncology Group. Clinical Cancer Res 2006; 12:1750-59.

Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khaz D, Winter C, Okowa E, Grant G, Cnaan A, Zhao H, Cheung NK, Gerald W, London W, Matthay KK, Brodeur GM, Maris JM. Integrative genomics identifies distinct molecular classes of neuroblastoma and demonstrates that multiple genes are targeted by regional alterations in DNA copy number. Cancer Research 2006; 66:6050-62.

12/15/06